Protein released from cells triggers chain reactions that could cause Alzheimer's disease

November 28, 2013, University of Cambridge
Credit: University of Cambridge

Researchers have shown that tiny quantities of the protein tau can be enough to kick-start an aggregation process which may explain the onset of Alzheimer's in the brain.

A powerful laser imaging technique has been used by researchers to show how minute quantities of a protein associated with Alzheimer's Disease trigger a process which may be crucial to its onset and spread.

The study also potentially links neuronal damage – for example, through brain injury, or head injuries sustained in contact sports – to the onset of Alzheimer's.

The researchers involved, however, are urging caution about the results, stressing that the study used a model cell culture and that the processes, which enable the disease to take root and develop in the brain could be far more complicated.

"These are molecular-level glimpses of what may be going on," Clemens Kaminski, Professor of Chemical Physics at the University of Cambridge, who led the research, said. "We are just beginning to see the molecular steps that may provide an explanation for what we see in the brains of patients who have died of Alzheimer's."

The study, reported in The Journal Of Biological Chemistry, focused on tau, a protein normally found inside healthy . In the brains of people who have died of Alzheimer's, however, clusters of malfunctioning tau are also found, and these appear to play a critical role in preventing their brain cells from working properly.

In the new study, researchers investigating how this happens added tiny quantities of normal tau to the outside of brain cells. To their surprise, the cells immediately started to ingest the protein. The ensuing uptake process, called endocytosis, kick-started aggregation of the protein into clumps. These clumps were then observed to cause "healthy tau" inside cells to misbehave and also aggregate.

Although seen in model cell cultures, the observations may show how the events that cause Alzheimer's begin. If so, there are practical implications: tau can be released into fluid around the brain, and therefore become a candidate for ingestion by other cells, through repeated head injuries, such as those suffered in contact sports. This, however, is only one process by which the protein is released.

The aggregation process which forms clusters of tau is also linked to other diseases, including certain forms of brain cancer and Parkinson's. By drawing attention to a potential root cause of Alzheimer's, the research could eventually enable the development of therapies targeting the underlying problems in the brain, which stimulate its spread.

"The study underlines how significant the uptake of small quantities of tau might be as an initiator for the conditions that then prevail in the brains of Alzheimer's sufferers," Kaminski added. "It is one piece in the puzzle that could provide us with an explanation as to why may be connected to the disease. It's not necessarily correct – but it is plausible."

Tau – an abbreviation of Tubulin Associated Protein Unit – has long been linked with Alzheimer's, and researchers trying to find a cure have focused on attempting to understand how dysfunctional tau emerges and how it spreads.

To do this, however, they need to be able to observe events at a molecular level. The Cambridge Laser Analytics Group, to which Kaminski and his colleagues belong, is a team of physicists, biologists, chemists and engineers who, over many years, have developed laser-based imaging techniques to watch these basic chemical processes and study the molecular mechanisms that lie behind diseases like Alzheimer's.

During the new study, normal, monomeric tau protein was placed into a model system of neuronal cell lines and then watched through super-high resolution microscopes as the team tracked the effects. For the first time, this enabled them to watch monomeric tau form dysfunctional clumps which infected healthy tau and caused it to malfunction.

The ingestion process appeared to be caused by fat droplets, used by the cell to take on nutrients. As foreign tau enters the cell, a nucleation event takes place, during which the first clumps are formed. The tau already inside the cell then aggregates with these, causing the protein to misbehave. The newly-formed polymer then emerges from the cell and can potentially infect others.

"What is striking is that small concentrations of healthy tau form clumps when ingested into cells. We would never have thought that this could lead to the formation of potentially harmful aggregates," Dr Claire Michel, who performed the experiments, said. "The processes during ingestion could be crucial in the context of the disease."

The team's future research will focus on identifying how and where a molecule of tau entering a neuronal cell meets the tau already inside it, and also on how the aggregated clusters of tau emerge. This could pinpoint targets for future treatments.

While a lot of research into therapies has focused on how to remove clusters of tau from the brain, this latest investigation suggests that preventing individual monomers from entering cells might be just as essential.

"Our priority now is to connect what we have observed to the pathology of the disease," Dr Gabriele Kaminski-Schierle, who led biological aspects of the research, said. "We still do not know if we can stop cells from ingesting tau, or whether we can somehow wash tau out of the brain fluid. Answering these questions is key to developing future therapies to treat what remains, at the moment, a terrible and incurable disease."

Dr Simon Ridley, Head of Research at Alzheimer's Research UK, said: "The state-of-the-art technology used by this research team allows a unique insight into the molecular events that occur in Alzheimer's. Investigating how the spreads between nerve cells can help researchers better understand what causes the disease and offer new approaches for treatments. It is unclear from this study whether head injury could trigger this molecular process, but it is a risk factor for dementia that needs to be investigated further."

Explore further: Newly identified antibodies effectively treat Alzheimer's-like disease in mice

More information: … M113.515445.abstract

Related Stories

Newly identified antibodies effectively treat Alzheimer's-like disease in mice

September 26, 2013
Alzheimer's disease is characterized by the accumulation of particular toxic proteins in the brain that are believed to underlie the cognitive decline in patients. A new study conducted in mice suggests that newly identified ...

Stress-related protein speeds progression of Alzheimer's disease

September 4, 2013
A stress-related protein genetically linked to depression, anxiety and other psychiatric disorders contributes to the acceleration of Alzheimer's disease, a new study led by researchers at the University of South Florida ...

Fluorescent compounds allow clinicians to visualize Alzheimer's disease as it progresses

September 18, 2013
What if doctors could visualize all of the processes that take place in the brain during the development and progression of Alzheimer's disease? Such a window would provide a powerful aid for diagnosing the condition, monitoring ...

Neuronal activity induces tau release from healthy neurons

February 15, 2013
Researchers from King's College London have discovered that neuronal activity can stimulate tau release from healthy neurons in the absence of cell death. The results published by Diane Hanger and her colleagues in EMBO reports ...

From trauma to tau: Researchers tie brain injury to toxic form of protein

May 29, 2013
University of Texas Medical Branch at Galveston researchers have uncovered what may be a key molecular mechanism behind the lasting damage done by traumatic brain injury.

Receptor may aid spread of Alzheimer's and Parkinson's in brain

August 23, 2013
(Medical Xpress)—Scientists at Washington University School of Medicine in St. Louis have found a way that corrupted, disease-causing proteins spread in the brain, potentially contributing to Alzheimer's disease, Parkinson's ...

Recommended for you

How your brain remembers what you had for dinner last night

January 17, 2018
Confirming earlier computational models, researchers at University of California San Diego and UC San Diego School of Medicine, with colleagues in Arizona and Louisiana, report that episodic memories are encoded in the hippocampus ...

Recording a thought's fleeting trip through the brain

January 17, 2018
University of California, Berkeley neuroscientists have tracked the progress of a thought through the brain, showing clearly how the prefrontal cortex at the front of the brain coordinates activity to help us act in response ...

Midbrain 'start neurons' control whether we walk or run

January 17, 2018
Locomotion comprises the most fundamental movements we perform. It is a complex sequence from initiating the first step, to stopping when we reach our goal. At the same time, locomotion is executed at different speeds to ...

A 'touching sight': How babies' brains process touch builds foundations for learning

January 16, 2018
Touch is the first of the five senses to develop, yet scientists know far less about the baby's brain response to touch than to, say, the sight of mom's face, or the sound of her voice.

Brain zaps may help curb tics of Tourette syndrome

January 16, 2018
Electric zaps can help rewire the brains of Tourette syndrome patients, effectively reducing their uncontrollable vocal and motor tics, a new study shows.

Researchers identify protein involved in cocaine addiction

January 16, 2018
Mount Sinai researchers have identified a protein produced by the immune system—granulocyte-colony stimulating factor (G-CSF)—that could be responsible for the development of cocaine addiction.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Nov 28, 2013
Great work. APOE is involved with lipid transport in the blood and its different variants are strongly associated with Alzheimer's. Does the ingestion of tau differ depending on whether the patient expresses APOE2, APOE3 or APOE4? Is this question relevant for the tissue cultures used?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.